Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Fai… (NCT07547449) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Failure
China140 participantsStarted 2026-04
Plain-language summary
This is a multi-center, prospective, single-blind, randomized controlled clinical trial to evaluate the efficacy and safety of Bachmann bundle pacing (BBP) in preventing new-onset atrial fibrillation (AF) in patients with chronic cardiac insufficiency who have indications for cardiac resynchronization therapy with left bundle branch pacing (CRT/LBBP) or implantable cardioverter defibrillator (ICD) implantation.
A total of 110 eligible patients will be randomly assigned 1:1 to the BBP group or the traditional right atrial appendage (RAA) pacing group. All patients will receive guideline-directed medical therapy (GDMT) for at least 3 months and standardized follow-up for 12 months after device implantation. The primary endpoint is the incidence of new-onset AF within 12 months after implantation. Secondary endpoints include time to first new-onset AF, procedural success rate, changes in cardiac function parameters, and incidence of adverse events. This study aims to provide high-level evidence-based medical evidence for BBP as a new atrial pacing strategy to prevent AF in heart failure patients.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged between 18 and 70 years old;
✓. Diagnosis of chronic cardiac insufficiency according to current guidelines, and received guideline-directed medical therapy (GDMT) for at least 3 months;
✓. Have indications for CRT/LBBP or ICD implantation, and expected atrial pacing ratio \> 20%, including: Sinus rhythm, QRS duration \> 120ms, LBBB, LVEF ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration ≥ 150ms, non-LBBB, LVEF ≤ 35% with symptomatic heart failure; Sinus rhythm, QRS duration \> 120ms, LBBB, LVEF 36%-50% with symptomatic heart failure; Symptomatic heart failure with LVEF ≤ 50% and expected ventricular pacing ratio \> 20%; Symptomatic heart failure with LVEF ≤ 50% requiring ICD implantation for primary or secondary sudden death prevention, with atrial pacing indication due to sinus bradycardia or expected atrial pacing ratio \> 20%;
✓. Patients with pacing-induced cardiomyopathy requiring upgrade therapy, in sinus rhythm, and requiring reimplantation of atrial lead;
✓. Signed written informed consent form approved by the ethics committee.
Exclusion criteria
✕. Expected survival time less than 12 months;
What they're measuring
1
Incidence of New-Onset Atrial Fibrillation
Timeframe: 12 months after device implantation
2
Time to Onset of New-Onset Atrial Fibrillation Post-Device Implantation
Timeframe: Up to 12 months after device implantation
. Status after mechanical tricuspid valve replacement, or congenital heart disease (including dextrocardia, transposition of great arteries, single left persistent superior vena cava);
✕. Previous history of atrial fibrillation;
✕. Previous cardiac surgery, or requiring surgical treatment for severe structural heart disease within 1 year;
✕. Pregnancy, planned pregnancy, or heart transplantation;